Pfizer (PFE) Reports Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin (trastuzumab) at ESMO 2017
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) today announced positive findings from REFLECTIONS B327-02 (n=707), a pivotal Phase 3 randomized, double-blind comparative safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
